Eylea biosimilars from Amgen and Samsung are eating their lunch. Base Eylea sales fell like 25% last quarter, and that franchise used to be 40% of their revenue. Luckily, Dupixent is still a monster. Almost $18 billion in global sales last year, up over 30% . And they just signed a deal with Telix to get into radiopharma for cancer. $40 million upfront. I'm going to wait this one out a bit longer to see how things develop from here.
There are no replies in this thread yet. Be the first to post a reply below: